XP13512

XP13512 is our most advanced product candidate. XP13512 is in clinical development as a potential treatment for restless legs syndrome, or RLS, post-herpetic neuralgia, or PHN, painful diabetic neuropathy, or PDN, and migraine prophylaxis. It is a Transported Prodrug of gabapentin, a drug that has been sold by Pfizer Inc as Neurontin since 1993 and is currently sold as a generic drug by a number of companies.

XP13512 is a patented new chemical entity discovered by XenoPort. We have licensed rights to develop and commercialize XP13512 to Astellas Pharma Inc. in Japan and five Asian countries and to GlaxoSmithKline, or GSK, in all other regions of the world.